[Cell therapy in renal cell carcinoma].
Cellular therapy in renal cell carcinoma has to be included in a strategy based on the known sensitivity to immunotherapy of renal cell carcinoma. Cellular therapy was previously initiated with Lymphokine Activated Killer cells (LAK) then Tumor Infiltrating Lymphocytes (TIL). Yet, major clinical evaluations are performed on dendritic cells and allogeneic blood stem cell transplantation.
Ravaud
Alain
A
Service de cancérologie, hôpital Saint-André, CHU, 1, rue Jean Burguet, 33075 Bordeaux, France. alain.ravaud@chu-bordeaux.fr
D000938:Antigen-Presenting Cells / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000637:transplantation*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation*; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology / Q000637:transplantation*